(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
8 March 2012 (08.03.2012)

PCT

(10) International Publication Number
WO 2012/031140 A1

(51) International Patent Classification:
A61K 39/00 (2006.01) *C07D 471/04* (2006.01)
A61K 39/095 (2006.01) *C07D 239/48* (2006.01)
C07D 487/04 (2006.01)

(21) International Application Number:
PCT/US2011/050231

(22) International Filing Date:
1 September 2011 (01.09.2011)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

61/379,126	1 September 2010 (01.09.2010)	US
61/448,394	2 March 2011 (02.03.2011)	US
61/466,887	23 March 2011 (23.03.2011)	US

(71) Applicants *(for all designated States except US)*: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH). **IRM LLC**; 131 Front Street, P.o. Box Hm 2899, Hamilton, HM LX (BM).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **SINGH, Manmohan** [US/US]; C/o Novartis Vaccines And Diagnostics, Inc., Po Box 8097, Emeryville, CA 94662-8097 (US). **SKIBINSKI, David, A.g.** [GB/SG]; C/o Novartis Vaccines And Diagnostics, Inc., Po Box 8097, Emeryville, CA 94662-8097 (US). **WU, Tom, Yao-hsiang** [US/US]; Genomics Institute Of The Novartis Foundation, 10675 John Jay Hopkins Drive, San Diego, CA (US). **LI, Yongkai** [US/US]; Genomics Institute Of The Novartis Foundation, 10675 John Jay Hopkins Drive, San Diego, CA (US). **CORTEZ, Alex** [US/US]; Genomics Institute Of The Novartis Foundation, 10675 John Jay Hopkins Drive, San Diego, CA (US). **ZHANG, Xiaoyue** [CN/US]; Genomics Institute Of The Novartis Foundation, 10675 John Jay Hopkins Drive, San Diego, CA (US). **ZOU, Yefen** [CN/US]; Genomics Institute Of The Novartis Foundation, 10675 John Jay Hopkins Drive, San Diego, CA (US). **HOFFMAN, Timothy, Z.** [US/US]; Genomics Institute Of The Novartis Foundation, 10675 John Jay Hopkins Drive, San Diego, CA (US). **PAN, Jianfeng** [CN/US]; Genomics Institute Of The Novartis Foundation, 10675 John Jay Hopkins Drive, San Diego, CA (US). **YUE, Kathy** [US/US]; Genomics Institute Of The Novartis Foundation, 10675 John Jay Hopkins Drive, San Diego, CA (US).

(74) Agents: **LEE, Helen** et al.; Novartis Vaccines And Diagnostics, Inc., Ip Services M/s X-100b, Po Box 8097, Emeryville, CA 94662-8097 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

— *with sequence listing part of description (Rule 5.2(a))*

(54) **Title**: ADSORPTION OF IMMUNOPOTENTIATORS TO INSOLUBLE METAL SALTS

(57) **Abstract**: Immunopotentiators can be adsorbed to insoluble metal salts, such as aluminium salts, to modify their pharmacokinetics, pharmacodynamics, intramuscular retention time, and/or immunostimulatory effect. Immunopotentiators are modified to introduce a moiety, such as a phosphonate group, which can mediate adsorption. These modified compounds can retain or improve their in vivo immunological activity even when delivered in an adsorbed form.

WO 2012/031140 A1